Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Archives

You are currently viewing the 2005 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: alendronate sodium

« Back to Dashboard

Alendronate sodium is the generic ingredient in two branded drugs marketed by Roxane, Merck, Mission Pharma, Apotex, Aurobindo Pharma, Austarpharma Llc, Cadista Pharms, Cipla Ltd, Dr Reddys Labs Ltd, Mylan, Sandoz, Sun Pharma Global, Teva Pharms, Watson Labs, and Merck And Co Inc, and is included in three NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty-five drug master file entries for alendronate sodium. Three suppliers are listed for this compound.

Summary for Generic Name: alendronate sodium

Tradenames:2
Patents:11
Applicants:1
NDAs:3
Drug Master File Entries: see list25
Suppliers: see list3
Therapeutic Class:Metabolic Bone Disease Agents

Pharmacology for Ingredient: alendronate sodium

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate

Clinical Trials for: alendronate sodium

The Effects of Alendronate After Cure of Primary Hyperparathyroidism
Status: Withdrawn Condition: Hyperparathyroidism

Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions
Status: Completed Condition: Healthy

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury Previously Treated With Teriparatide
Status: Enrolling by invitation Condition: Spinal Cord Injury; Bone Loss; Osteoporosis

Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
Status: Completed Condition: Cystic Fibrosis; Osteoporosis; Bone Diseases, Metabolic

A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)(COMPLETED)
Status: Completed Condition: Osteoporosis

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Status: Completed Condition: Osteopenia; Osteoporosis

Alendronate in Juvenile Osteoporosis
Status: Completed Condition: Juvenile Osteoporosis; Low Bone Density; Fractures

The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
Status: Completed Condition: Osteoporosis

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
Status: Completed Condition: Osteoporosis

A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
Status: Completed Condition: Postmenopausal Osteoporosis

Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
Status: Completed Condition: Osteoporosis Postmenopausal

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
Status: Active, not recruiting Condition: Heart Transplantation; Liver Transplantation; Bone Resorption

A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D
Status: Completed Condition: Osteoporosis

Pilot Study of Fosamax in Spinal Cord Injury
Status: Terminated Condition: Spinal Cord Injury; Osteoporosis

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.
Status: Completed Condition: Healthy

Safety and Effectiveness of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density
Status: Active, not recruiting Condition: HIV Infections

Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis
Status: Completed Condition: Osteoporosis

A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Status: Completed Condition: Postmenopausal Osteoporosis

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
Status: Withdrawn Condition: Osteoporosis; Postmenopausal Osteoporosis

Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis
Status: Completed Condition: Osteoporosis

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults
Status: Recruiting Condition: Hepatitis B

Denosumab Adherence Preference Satisfaction Study
Status: Completed Condition: Osteoporosis

Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
Status: Completed Condition: Osteoporosis

FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
Status: Completed Condition: Osteoporosis

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
Status: Active, not recruiting Condition: Renal Insufficiency

Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
Status: Completed Condition: Osteoporosis

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
Status: Completed Condition: Osteopenia; Osteoporosis

Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease
Status: Completed Condition: Vascular Calcification; Arteriosclerosis

Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
Status: Completed Condition: Osteoporosis

Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
Status: Completed Condition: Osteoporosis

Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
Status: Active, not recruiting Condition: Coronary Artery Stenosis

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)
Status: Completed Condition: Healthy

Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)
Status: Completed Condition: Healthy

Osteoporosis Prevention With Low Dose Alendronate
Status: Completed Condition: Osteopenia

Testosterone and Alendronate in Hypogonadal Men
Status: Recruiting Condition: Hypogonadism; Osteopenia; Osteoporosis

Treatment of Low Bone Density in Cystic Fibrosis.
Status: Completed Condition: Osteoporosis; Cystic Fibrosis

OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism
Status: Completed Condition: Primary Hyperparathyroidism

Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
Status: Active, not recruiting Condition: Post-menopausal Osteoporosis

Fosamax for Childhood Cancer Survivors
Status: Recruiting Condition: Osteoporosis

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
Status: Completed Condition: Osteoporosis

The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)
Status: Terminated Condition: Back Pain

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate
Status: Completed Condition: Postmenopausal Osteoporosis

Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
Status: Terminated Condition: Osteoporosis

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
Status: Completed Condition: Breast Cancer

Study of Transitioning From Alendronate to Denosumab
Status: Completed Condition: Postmenopausal Osteoporosis

A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
Status: Completed Condition: Osteoporosis, Postmenopausal

Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)
Status: Active, not recruiting Condition: Ankylosing Spondylitis; Osteoporosis

Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
Status: Completed Condition: End-Stage Renal Disease; Osteoporosis

A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
Status: Completed Condition: Osteoporosis; Osteopenia

Alendronate to Prevent Loss of Bronchoprotection in Asthma
Status: Not yet recruiting Condition: Asthma

1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers
Status: Completed Condition: Chronic Periodontitis

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
Status: Terminated Condition: Stage IV Prostate Cancer; Bone Metastases; Adenocarcinoma of the Prostate; Recurrent Prostate Cancer

Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?
Status: Not yet recruiting Condition: Peritoneal Dialysis

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Status: Completed Condition: Low Bone Mineral Density

RA Denosumab on Bone Microstructure Study
Status: Completed Condition: Rheumatoid Arthritis

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Status: Completed Condition: Osteoporosis

Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
Status: Terminated Condition: Osteopenia; Osteoporosis

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Status: Recruiting Condition: Postmenopausal Women With Osteoporosis

Alendronate and/or Parathyroid Hormone for Osteoporosis
Status: Completed Condition: Osteoporosis

Alendronate Osteoporosis Study
Status: Active, not recruiting Condition: Glucocorticoid-Associated Osteopenia and Osteoporosis

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)
Status: Completed Condition: Osteoporosis; Postmenopausal Osteoporosis

Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)
Status: Completed Condition: Osteoporosis; HIV Infections

Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis
Status: Active, not recruiting Condition: Non-Traumatic Osteonecrosis

Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
Status: Completed Condition: Osteogenesis Imperfecta

Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
Status: Completed Condition: Rheumatoid Arthritis; Polymyalgia Rheumatica; Giant Cell Arteritis; Polymyositis; Wegener’s Granulomatosis

Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Status: Recruiting Condition: HIV

Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
Status: Completed Condition: Osteoporosis

Upper GI Handling of Branded vs. Generic Alendronate
Status: Completed Condition: Osteoporosis

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
Status: Completed Condition: Osteoporosis, Postmenopausal

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
Status: Completed Condition: Perimenopausal Bone Loss

A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
Status: Completed Condition: Osteoporosis, Postmenopausal

Treatment of Childhood Osteoporosis With Alendronate (Fosamax)
Status: Completed Condition: Osteoporosis

Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
Status: Completed Condition: Polyostotic Fibrous Dysplasia

The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients
Status: Completed Condition: HIV Infections

Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly
Status: Recruiting Condition: Alveolar Bone Healing After Dental Extraction

Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.
Status: Recruiting Condition: Calcific Aortic Stenosis

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
Status: Completed Condition: Post-Menopausal Osteoporosis

A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
Status: Completed Condition: Postmenopausal Osteoporosis

The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Status: Recruiting Condition: Osteoporosis

A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
Status: Completed Condition: Post-Menopausal Osteoporosis

The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)
Status: Active, not recruiting Condition: Bone Density; Arthroplasty, Replacement, Hip

4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)(COMPLETED)
Status: Completed Condition: Osteoporosis

Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
Status: Recruiting Condition: Osteoporosis

99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Decreased Bone Mineral Density
Status: Not yet recruiting Condition: Differentiated Thyroid Cancer; Osteoporosis

Osteoporosis and Dental Implant
Status: Recruiting Condition: Osteoporosis

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease
Status: Recruiting Condition: Gaucher's Disease; Osteopenia

A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)
Status: Completed Condition: Osteoporosis

Transition From Alendronate to AMG 785
Status: Completed Condition: OSTEOPOROSIS, POSTMENOPAUSAL

Glucocorticoids Promote Osteoclast Survival
Status: Terminated Condition: Osteoporosis

Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
Status: Completed Condition: Esophageal Cancer; Squamous Cell Carcinoma; Adenocarcinoma

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
Status: Recruiting Condition: Osteoporosis; Cystic Fibrosis

Network Osteoporosis Study
Status: Active, not recruiting Condition: Osteopenia; Osteoporosis

FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
Status: Completed Condition: Osteoporosis, Postmenopausal

Cyclic Versus Daily Teriparatide on Bone Mass
Status: Active, not recruiting Condition: Osteoporosis

Bone Loss in Premenopausal Women With Depression
Status: Completed Condition: Depression; Healthy; Osteopenia; Osteoporosis

Effects of Parathyroid Hormone in Men With Osteoporosis
Status: Completed Condition: Osteoporosis

EVA: Evista Alendronate Comparison
Status: Completed Condition: Osteoporosis

Bone Effects of Teriparatide Following Alendronate
Status: Completed Condition: Osteoporosis

A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
Status: Completed Condition: Osteoporosis, Postmenopausal

Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
Status: Completed Condition: Osteoporosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Merck
FOSAMAX
alendronate sodium
TABLET; ORAL020560Apr 25, 1997RXNo<disabled><disabled>
Merck
FOSAMAX
alendronate sodium
TABLET; ORAL020560Oct 20, 2000RXYes4,621,077*PED<disabled><disabled>
Merck
FOSAMAX
alendronate sodium
TABLET; ORAL020560Oct 20, 2000RXYes5,358,941*PED<disabled><disabled>
Merck
FOSAMAX
alendronate sodium
TABLET; ORAL020560Oct 20, 2000RXYes5,994,329*PED<disabled><disabled>
Merck
FOSAMAX
alendronate sodium
TABLET; ORAL020560Oct 20, 2000RXNo5,681,590*PED<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc